Novartis AG reaffirmed its excitement about the commercial potential of the chimeric antigen receptor T cell (CAR-T) therapy CTL019 during a meet-the-management event at the company's research campus in Cambridge, Mass. May 31.
CEO Joseph Jimenez pointed to the pricing potential in CAR-T as one of the reasons for optimism. Novartis has a lot riding on the success of CAR-T because the company...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?